Nektar Therapeutics has received $-0.26 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 6 Financial Advisor in the Stock Trading Firms. Among 6 Analysts, Bottom line EPS Estimate for the current quarter is $-0.31 while the top line estimate is $-0.22 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 35%.
Nektar Therapeutics reported better than expected with a surprise EPS of 5.88% or $0.02 during its most recent quarterly earnings. The Actual EPS was $-0.32 compared to the Estimated EPS of $-0.34. San Francisco based Nektar Therapeutics Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Mar 07, 2017.
In the last quarter, Nektar Therapeutics reported Annual Earnings of $-0.32. Based on the filings, last years Annual Earnings was, $-0.61. In the last Quarter, NKTR reported a surprise Earnings per Share of 5.88% . The consensus estimate for current quarter is $-0.26 and for the current fiscal year, the estimate is $-1.07. For the Next fiscal year, the estimate is $-0.82 based on the consensus.
Nektar Therapeutics (NASDAQ:NKTR) : On Tuesday heightened volatility was witnessed in Nektar Therapeutics (NASDAQ:NKTR) which led to swings in the share price. The stock opened for trading at $11.65 and hit $12.14 on the upside , eventually ending the session at $12.11, with a gain of 3.06% or 0.36 points. The heightened volatility saw the trading volume jump to 1,589,827 shares. The 52-week high of the share price is $19.98 and the company has a market cap of $1,851 million. The 52-week low of the share price is at $10.52 .
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to meet unmet medical needs and improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain. In the area of pain, Nektar has a worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies as a once-daily, oral tablet for the treatment of opioid-induced constipation. The agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of NKTR-118 and an opioid. Also in the area of pain, NKTR-181, the companys wholly-owned novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies. Nektar Therapeutics is headquartered in San Francisco, California.